I-Corps: A novel gene assay for accurate prognosis and prediction of clinical benefits of chemotherapy for early-stage non-small cell lung cancer

这个i-Corps项目的更广泛的影响/商业潜力是开发一种分析方法，解决非小细胞肺癌(NSCLC)患者在初级肿瘤手术切除时肿瘤复发的高发生率问题。该产品可能成为第一阶段NSCLC患者在手术切除原发肿瘤时的标准护理的一部分，并被用于识别那些将从早期实施化疗以防止肿瘤进展和复发中受益的高危患者。建议的7基因检测的临床应用可能会改善肺癌患者的护理和预后，并降低由于初步治疗失败而导致的支付者的医疗费用。这个I-Corps项目基于开发的7基因标记小组，该小组可以准确预测所有组织亚型早期非小细胞肺癌患者的复发风险。利用新的人工智能(AI)方法，该分析还预测了在概念验证训练和验证样本集中接受辅助化疗的临床好处。这项7基因检测可能会识别初次肿瘤切除后癌症复发的高风险早期非小细胞肺癌患者，告知肿瘤学家复发的风险以改善患者管理，并建议对高风险的1期非小细胞肺癌患者尽早实施以铂为基础的化疗。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is the development of an assay that addresses the high incidence of tumor recurrence in patients with non-small cell lung cancer (NSCLC) at the time of primary tumor surgical resection. The product may become part of the standard of care for stage 1 NSCLC patients at the time of surgical resection of the primary tumor, and be used to identify those at high-risk who would benefit from early implementation of chemotherapy to prevent tumor progression and recurrence. Clinical application of the proposed 7-gene assay may improve patient care and outcomes for those with lung cancer and reduce healthcare costs for the payers resulting from the failure of initial treatment.This I-Corps project is based on the development of a 7-gene marker panel that accurately predicts the risk of recurrence in early-stage NSCLC patients for all histological subtypes. Employing novel artificial intelligence (AI) methods, the assay also predicts the clinical benefits of receiving adjuvant chemotherapy in both proof-of-concept training and validation sample sets. This 7-gene assay may identify high-risk early-stage NSCLC patients following primary tumor resection for cancer recurrence, inform oncologists of the risk of recurrence to improve patient management, and recommend early implementation of platinum-based chemotherapy for high-risk stage 1 NSCLC patients.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.